Severe COVID-19 multisystem inflammatory syndrome versus severe dengue in children from Indonesia: a cross-sectional study
- PMID: 38992604
- PMCID: PMC11242006
- DOI: 10.1186/s12245-024-00658-6
Severe COVID-19 multisystem inflammatory syndrome versus severe dengue in children from Indonesia: a cross-sectional study
Abstract
Introduction: Severe multisystem inflammatory syndrome in children (MIS-C) and severe dengue are challenging to identify during the COVID-19 pandemic in dengue-endemic areas. Fever, multiorgan involvement, and shock characterize both severe MIS-C and severe dengue. Distinguishing between the two diseases is beneficial in initiating proper management.
Methods: Medical records of children < 18 years old who were hospitalized at Hasan Sadikin General Hospital's PICU between December 2020 and July 2022 with severe MIS-C or severe dengue were recorded. Differences were assessed using comparative and descriptive analyses.
Results: Seventeen severe dengue patients and 4 severe MIS-C were included. The average age of severe MIS-C was 11.5 years (SD ± 2.9, 95% CI), and that of severe dengue patients was 6.2 years (SD ± 4.4, 95% CI) (p value = 0.034, 95%). Fever and abdominal pain were the most common symptoms in both groups (p = 0.471, 95% CI). Rash (p = 0.049) and nonpurulent conjunctivitis (p = 0.035) were two symptoms with significant differences. The highest platelet count (p-value = 0.006, 95% CI), AST (p-value = 0.026, 95% CI), and D-dimer level (p-value = 0.025, 95% CI) were significantly different between the two cohorts. Cardiac abnormalities were found in all (100%) severe MIS-C patients, but only one (5.9%) in severe dengue patients.
Conclusion: Age, rash, nonpurulent conjunctivitis, platelet count, AST and D-dimer level may distinguish severe MIS-C from severe dengue fever.
Keywords: Clinical manifestations; Laboratory parameters; Severe MIS-C; Severe dengue.
© 2024. The Author(s).
Conflict of interest statement
The authors declare no competing interests.
Similar articles
-
Comparison of Clinical Features and Outcome of Dengue Fever and Multisystem Inflammatory Syndrome in Children Associated With COVID-19 (MIS-C).Indian Pediatr. 2021 Oct 15;58(10):951-954. doi: 10.1007/s13312-021-2329-9. Epub 2021 Jul 23. Indian Pediatr. 2021. PMID: 34302327 Free PMC article.
-
Comparison of Multisystem Inflammatory Syndrome (MIS-C) and Dengue in Hospitalized Children.Indian J Pediatr. 2023 Jul;90(7):654-659. doi: 10.1007/s12098-022-04184-2. Epub 2022 May 5. Indian J Pediatr. 2023. PMID: 35511400 Free PMC article.
-
Clinical Subphenotypes of Multisystem Inflammatory Syndrome in Children: An EHR-based cohort study from the RECOVER program.medRxiv [Preprint]. 2022 Sep 27:2022.09.26.22280364. doi: 10.1101/2022.09.26.22280364. medRxiv. 2022. Update in: Sci Rep. 2023 Nov 28;13(1):21005. doi: 10.1038/s41598-023-47655-y. PMID: 36203555 Free PMC article. Updated. Preprint.
-
Epidemiology, Clinical Features, and Outcomes of Multisystem Inflammatory Syndrome in Children (MIS-C) and Adolescents-a Live Systematic Review and Meta-analysis.Curr Pediatr Rep. 2022;10(2):19-30. doi: 10.1007/s40124-022-00264-1. Epub 2022 May 6. Curr Pediatr Rep. 2022. PMID: 35540721 Free PMC article. Review.
-
COVID-19 Associated Multisystem Inflammatory Syndrome: A Systematic Review and Meta-analysis.Iran J Allergy Asthma Immunol. 2020 Dec 19;19(6):570-588. doi: 10.18502/ijaai.v19i6.4927. Iran J Allergy Asthma Immunol. 2020. PMID: 33463127
References
-
- Xiaoxia Lu MD, Liqiong Zhang MD, Hui Du M. SARS CoV-2 Infection in Children.; 2020. 10.1056/NEJMc2005073.
-
- Farooqi KM, Chan A, Weller RJ, et al. Longitudinal outcomes for multisystem inflammatory syndrome in children. Pediatrics. 2021;148(2). 10.1542/peds.2021-051155. - PubMed
LinkOut - more resources
Full Text Sources